Product image of Iasocholine (Fluorocholine (18f) Chloride) supplied by GNH India

Iasocholine

Active Ingredient:
Fluorocholine (18f) Chloride
Origin:
EU

Iasocholine (Fluorocholine (18f) Chloride)

Fluorocholine (18F) chloride, the active ingredient in Iasocholine, is an imaging agent presented as an injectable solution for intravenous use. It is used in positron emission tomography (PET) imaging to assess metabolic activity in tumors and other tissues.

GNH India supplies Iasocholine as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres and imaging clinics worldwide.

Manufacturer / TM Owner

Curium Austria Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Iasocholine is employed as a radiotracer in PET imaging for several clinical pathways.
  • Oncologic PET imaging: helps visualize tumor metabolism and detect malignant lesions.
  • Neurological PET imaging: assesses brain lesions, gliomas and epileptogenic foci.
  • Cardiac PET imaging: evaluates myocardial viability and perfusion abnormalities.

How It Works

  • Fluorocholine (18F) chloride is a radiolabeled choline analog that enters cells via choline transporters and is phosphorylated by choline kinase, becoming incorporated into phosphatidylcholine synthesis. Cells with high membrane turnover, such as cancer or activated brain tissue, accumulate the tracer, allowing PET scanners to generate high‑contrast images of metabolic activity.

Side Effects

Iasocholine may cause a range of adverse reactions following intravenous administration.

Common Side Effects

  • Nausea: mild to moderate discomfort after injection.
  • Injection site pain: transient soreness at the venipuncture site.
  • Headache: usually brief and self‑limiting.
  • Flushing: temporary warmth and redness.
  • Dizziness: mild light‑headedness.
  • Transient hypertension: short‑lived rise in blood pressure.

Serious or Rare Side Effects

  • Allergic reaction or anaphylaxis: severe hypersensitivity requiring immediate medical attention.
  • Severe hypotension: sudden drop in blood pressure.
  • Arrhythmia: irregular heart rhythm.
  • Radiation‑induced skin injury: localized erythema at high exposure sites.
  • Renal toxicity: impaired kidney function in susceptible patients.
  • Severe allergic response: including bronchospasm or angioedema.

Precautions & Warnings

  • Prior to using Iasocholine, clinicians should consider several safety measures.
  • Renal impairment: assess kidney function and adjust use if necessary.
  • Pregnancy: avoid unless essential, due to ionizing radiation exposure.
  • Breastfeeding: discontinue breastfeeding for an appropriate interval after administration.
  • Allergy to iodine or radiopharmaceuticals: evaluate risk before injection.
  • Concurrent chemotherapy: monitor for additive toxicities.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Iasocholine may interact with other agents that affect imaging quality or radiation exposure.

Major Interactions (Avoid)

  • Therapeutic radiopharmaceuticals: concurrent use can increase total radiation dose.
  • High‑dose steroids: may reduce tracer uptake and compromise image interpretation.
  • Iodinated contrast agents: can interfere with PET signal and should be spaced appropriately.

Moderate Interactions (Monitor Closely)

  • Chemotherapeutic agents: monitor for overlapping toxicities, especially renal effects.
  • Anticoagulants: observe for bleeding at the injection site.
  • Other diagnostic agents: schedule to avoid cross‑interference in imaging studies.

Frequently Asked Questions

Iasocholine is a radiopharmaceutical used primarily for positron emission tomography (PET) scans. It helps visualize metabolic activity in tumors, brain lesions, and cardiac tissue, providing clinicians with detailed functional images that support diagnosis, staging, and treatment planning.

Fluorocholine (18F) chloride is a choline analogue that is taken up by cells via choline transporters and phosphorylated by choline kinase. Because rapidly dividing or activated cells increase phospholipid synthesis, the tracer accumulates in those areas, allowing PET scanners to detect and map high‑metabolism regions.

The dose of Iasocholine is determined by the prescribing physician based on the specific imaging protocol, patient weight, and the required activity measured in megabecquerels (MBq). Exact dosing regimens are individualized and should follow institutional guidelines and radiopharmacy standards.

Iasocholine contains a radioactive isotope and is generally avoided in pregnant or breastfeeding individuals unless the diagnostic benefit outweighs the potential risk. Radiation exposure to the fetus or infant can be harmful, so alternative non‑radiative imaging methods are preferred when possible.

To order Iasocholine, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

The most common alternative PET tracer is 18F‑FDG, which highlights glucose metabolism. Iasocholine targets choline metabolism, offering superior contrast in certain cancers (e.g., prostate) and brain tumors where FDG uptake may be low. Choice of tracer depends on the clinical question and tumor type.

Iasocholine must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. It should be kept in its original container until use, and any unused portion must be disposed of according to local radiopharmaceutical waste regulations.

Iasocholine is administered as a single intravenous injection, typically over a few seconds. After injection, a short uptake period (usually 10‑30 minutes) is observed before the patient is positioned in the PET scanner for image acquisition.

The most serious risks include severe allergic reactions such as anaphylaxis, significant radiation exposure leading to tissue injury, and rare events like arrhythmias or renal toxicity. Immediate medical attention is required if any severe reaction occurs.

Iasocholine should be avoided in patients with known hypersensitivity to iodine or radiopharmaceuticals, pregnant or nursing women unless absolutely necessary, and individuals with severe renal impairment where tracer clearance may be compromised.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Fluorocholine (18f) Chloride

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT